Date: 2011-11-03
Type of information: Private placement
Company: Curevac (Germany)
Investors: Baillie Gifford (UK) Chartwave Limited (UK) Coppel family, Elma Investments, Sigma Group, dievini Hopp BioTech holding (Germany) Dietmar Hopp (Germany) the Bill & Melinda Gates Foundation (USA)
Amount: $110 Million (€100 million)
Funding type: private placement
Planned used: Proceeds from the financing round will be used to further develop CureVac’s clinical pipeline of natural, chemically unmodified mRNA therapeutic and prophylactic product candidates. The new capital will also fund research and clinical development to expand
CureVac’s proprietary mRNA platform technology.
Others: * On November 3, 2015, CureVac, a clinical-stage biopharmaceutical company pioneering the field of mRNA-based technology, announced that it has raised about $110 million (€100 million) to enable accelerated expansion of its messenger RNA (mRNA) development platform and clinical-stage pipeline. This new financing round was led by Baillie Gifford, adding to the approximately $220 million CureVac has raised since its founding in 2000. The new investors, Baillie Gifford, Chartwave Limited, Coppel family, Elma Investments Ltd and Sigma Group, join existing investors dievini Hopp BioTech holding GmbH & Co. KG of Dietmar Hopp and the Bill & Melinda Gates Foundation.
In addition, CureVac has filed for a change of its legal form from a German limited liability company (GmbH) to a joint German stock corporation (AG). The change of legal form is part of a process of adapting the corporate structure to facilitate further international growth on the corporate level.
Therapeutic area: Cancer - Oncology
